SET/TAF-I Antikörper (AA 147-235)

Produktnummer ABIN7166106

Produktdetails anti-SET/TAF-I Antikörper

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Bindungsspezifität: AA 147-235

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser SET/TAF-I Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Kreuzreaktivität: Human

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Human Protein SET protein (147-235AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:500-1:5000,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu SET/TAF-I

Target: SET/TAF-I (SET) (SET Nuclear Oncogene (SET))

Andere Bezeichnung: SET (SET Produkte)

Synonyme: 2PP2A antikoerper, I2PP2A antikoerper, IGAAD antikoerper, IPP2A2 antikoerper, PHAPII antikoerper, TAF-I antikoerper, TAF-IBETA antikoerper, 2610030F17Rik antikoerper, 5730420M11Rik antikoerper, AA407739 antikoerper, I-2PP2A antikoerper, StF-IT-1 antikoerper, 2pp2a antikoerper, i2pp2a antikoerper, igaad antikoerper, ipp2a2 antikoerper, phapii antikoerper, set antikoerper, set-a antikoerper, set-b antikoerper, taf-ibeta antikoerper, wu:fb30g11 antikoerper, wu:fd16c08 antikoerper, SET nuclear proto-oncogene antikoerper, SET nuclear oncogene antikoerper, SET translocation antikoerper, SET nuclear proto-oncogene L homeolog antikoerper, SET nuclear proto-oncogene b antikoerper, SET antikoerper, Set antikoerper, LOC403555 antikoerper, set.L antikoerper, setb antikoerper

Hintergrund:

Background: Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins, however, isoform 2 specific activity is higher.

Aliases: 2PP2A antibody, HLA DR associated protein II antibody, HLA-DR-associated protein II antibody, I 2PP2A antibody, I-2PP2A antibody, I2PP2A antibody, IGAAD antibody, Inhibitor of granzyme A activated DNase antibody, Inhibitor of granzyme A-activated DNase antibody, Inhibitor of GzmA-activated DNase antibody, inhibitor-2 of protein phosphatase-2A antibody, IPP2A2 antibody, PHAPII antibody, Phosphatase 2A inhibitor I2PP2A antibody, protein phosphatase type 2A inhibitor antibody, Protein SET antibody, Set antibody, SET nuclear oncogene antibody, SET translocation antibody, SET translocation (myeloid leukemia-associated) antibody, SET_HUMAN antibody, TAF I antibody, TAF IBETA antibody, TAF-I antibody, TAFI antibody, Template activating factor I antibody, Template-activating factor I antibody, Template-Activating Factor-I, chromatin remodelling factor antibody

UniProt: Q01105

Pathways: Apoptose